Hepatocellular Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Hepatocellular clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 541 trials

Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

Metastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8+1 more
National Cancer Institute (NCI)92 enrolled4 locationsNCT06811116
Recruiting
Phase 1

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric Cancer+2 more
BeOne Medicines140 enrolled19 locationsNCT06427941
Recruiting
Not Applicable

Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients

Hepatocellular CarcinomaVariceal Bleeding
Chinese University of Hong Kong84 enrolled1 locationNCT05629845
Recruiting
Phase 2

A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma

Carcinoma, Hepatocellular
Asan Medical Center33 enrolled1 locationNCT07010497
Recruiting
Phase 2

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

Advanced Unresectable Hepatocellular Carcinoma
Riboscience, LLC.220 enrolled3 locationsNCT07175441
Recruiting
Not Applicable

Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors

Colorectal, CancerHepatocellular Carcinoma
Chinese University of Hong Kong40 enrolled1 locationNCT06077591
Recruiting

A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma

HCC - Hepatocellular CarcinomaCTTACE(Transcatheter Arterial Chemoembolization)
Zhongda Hospital250 enrolled1 locationNCT07351669
Recruiting
Phase 2

Phase 2 Study of WGI-0301 for Advanced HCC

Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd.60 enrolled4 locationsNCT06309485
Recruiting
Phase 1Phase 2

A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma
West China Hospital33 enrolled1 locationNCT07482059
Recruiting
Phase 1Phase 2

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Hepatocellular CarcinomaRefractory Solid TumorPediatric Solid Tumor+3 more
St. Jude Children's Research Hospital64 enrolled2 locationsNCT05468359
Recruiting
Phase 2

Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma
Centre Hospitalier Universitaire de Besancon105 enrolled14 locationsNCT05528952
Recruiting
Not Applicable

Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab

Hepatocellular Carcinoma
Centre Hospitalier Universitaire de Besancon120 enrolled10 locationsNCT06796114
Recruiting
Phase 2

A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.

Hepatocellular Carcinoma (HCC)
Akeso100 enrolled1 locationNCT07052253
Recruiting
Not Applicable

Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis

CirrhosisHepatocellular Carcinoma (HCC)
University of Aarhus617 enrolled6 locationsNCT07469319
Recruiting
Phase 1

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)
Shanghai Henlius Biotech246 enrolled51 locationsNCT07176650
Recruiting
Phase 2

A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma

Hepatocellular Carcinoma
University of Michigan Rogel Cancer Center20 enrolled1 locationNCT05901519
Recruiting
Not Applicable

FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer.

Liver CancerHepatocellular CarcinomaCirrhosis+1 more
Assistance Publique - Hôpitaux de Paris944 enrolled1 locationNCT05095714
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Locally Advanced Hepatocellular CarcinomaLocally Advanced MelanomaMetastatic Hepatocellular Carcinoma+7 more
National Cancer Institute (NCI)30 enrolled1 locationNCT06066138